2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2005
Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells.
Hendrickson J, Chadwick T, Roback J, Hillyer C, Zimring J. Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells. Blood 2005, 106: 1887. DOI: 10.1182/blood.v106.11.1887.1887.Peer-Reviewed Original ResearchTransfusion recipientsIgG subtypesHen egg lysozymeRecipient miceHost inflammationViral infectionCo-existing infectionsDifferent IgG subtypesHemolytic transfusion reactionsActivation of macrophagesInnate immune systemUnits of RBCsBlood group antigensHumoral immunizationMimic inflammationRecipient inflammationAlloantibody responsesRed blood cellsSerious sequelaeIgG responsesAntibody titersHumoral immunityHumoral responseIgG synthesisImmunomodulatory agents